{"filing":{"accession_number":"0001628280-26-061892","cik":"0002007191","ticker":"TLPPF","company_name":"Telix Pharmaceuticals Ltd","form":"6-K","filing_date":"2026-09-14","report_date":"2026-09-14","primary_document":"telix-6kpixclarafdaapproval.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/2007191/000162828026061892/telix-6kpixclarafdaapproval.htm"},"events":[{"id":33350,"run_id":30660,"accession_number":"0001628280-26-061892","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"This exhibit announces FDA approval of Pixclara® (floretyrosine F 18), Telix's first FDA-approved PET imaging drug for glioma (brain cancer). The approval represents a significant regulatory milestone and commercial expansion for the company's precision diagnostics portfolio, addressing an unmet medical need in a large addressable market (~24,000 new U.S. cases annually). While this is a material operational and regulatory achievement, it does not fit the specific event types (e.g., earnings_release, ma_activity, exec_appointment) and is best classified as an operational milestone—a material product approval and market entry event.","company_name":"Telix Pharmaceuticals Ltd","ticker":"TLPPF","filing_date":"2026-09-14","form":"6-K","submitted_at":null,"items":[{"id":36775,"accession_number":"0001628280-26-061892","item_number":"EX-99.1","item_title":"pixclaraapprovalvfinal.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This exhibit announces FDA approval of Pixclara® (floretyrosine F 18), Telix's first FDA-approved PET imaging drug for glioma (brain cancer). The approval represents a significant regulatory milestone and commercial expansion for the company's precision diagnostics portfolio, addressing an unmet medical need in a large addressable market (~24,000 new U.S. cases annually). While this is a material operational and regulatory achievement, it does not fit the specific event types (e.g., earnings_release, ma_activity, exec_appointment) and is best classified as an operational milestone—a material product approval and market entry event.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-14T20:54:17.840370+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":36775,"accession_number":"0001628280-26-061892","item_number":"EX-99.1","item_title":"pixclaraapprovalvfinal.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This exhibit announces FDA approval of Pixclara® (floretyrosine F 18), Telix's first FDA-approved PET imaging drug for glioma (brain cancer). The approval represents a significant regulatory milestone and commercial expansion for the company's precision diagnostics portfolio, addressing an unmet medical need in a large addressable market (~24,000 new U.S. cases annually). While this is a material operational and regulatory achievement, it does not fit the specific event types (e.g., earnings_release, ma_activity, exec_appointment) and is best classified as an operational milestone—a material product approval and market entry event.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-14T20:54:17.840370+00:00","company_name":"Telix Pharmaceuticals Ltd","ticker":"TLPPF","filing_date":"2026-09-14"}]}